Biogen Inc.

Equities

BIIB

US09062X1037

Market Closed - Nasdaq Other stock markets 08:00:00 13/12/25 am AEDT			5-day change	1st Jan Change
174.10 ^USD	+0.93%		-3.97%	+13.85%

01:01pm	Bitcoin hoarding company Strategy remains in Nasdaq 100	RE
12:14pm	Nasdaq says Biogen, CDW Corporation, GlobalFoundries, Lululemon Athletica, On Semiconductor, Trade Desk will be removed from Nasdaq 100 index	RE

Transcript : Biogen Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 12

Published on 12/03/2025 at 06:35 am AEDT - Modified on 12/03/2025 at 08:05 am AEDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Thank you guys for being here. Super excited to have Biogen management join Alisha. Thank you for making time. I'll let you kick things off.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Biogen Inc.

01:01pm	Bitcoin hoarding company Strategy remains in Nasdaq 100	RE
12:14pm	Nasdaq says Biogen, CDW Corporation, GlobalFoundries, Lululemon Athletica, On Semiconductor, Trade Desk will be removed from Nasdaq 100 index	RE
13/12	Morgan Stanley Adjusts Biogen Price Target to $156 From $149, Maintains Equalweight Rating	MT
13/12	Alzheimer's drug hunt learns from cancer fight's multi-target playbook	RE
13/12	Analysts flag risks for Strategy at Nasdaq 100 index reshuffle	RE
12/12	PREVIEW-Analysts flag risks for Strategy at Nasdaq 100 index reshuffle	RE
11/12	This Is Decision Day
10/12	Wells Fargo Adjusts Price Target on Biogen to $190 From $155, Maintains Equalweight Rating	MT
10/12	Analyst recommendations: Abbvie, Biogen, PepsiCo, Eli Lilly, Netflix…
10/12	HSBC Downgrades Biogen to Reduce From Hold, Adjusts Price Target to $143 From $144	MT
06/12	Stoke Therapeutics, Inc. and Biogen Inc. Present Data That Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome	CI
06/12	Stoke Therapeutics and Biogen present data that further support the disease-modifying potential of zorevunersen	RE
06/12	Biogen and Stoke Therapeutics present data that further support the disease-modifying potential of zorevunersen	RE
04/12	Biogen Shares New Leqembi Data on Slower Alzheimer's Progression, Injection Option	MT
04/12	Eisai Co., Ltd. and Biogen Inc. Present New Data	CI
04/12	Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment	RE
04/12	Health Care Up on Alzheimer's Hopes - Health Care Roundup	DJ
04/12	Biogen Inc. Presents at Piper Sandler 37th Annual Healthcare Conference, Dec-03-2025 11:30 AM
03/12	Biogen and Eisai Present New LEQEMBI Biomarker Data at Clinical Trials on Alzheimer's Disease 2025 Conference	MT
03/12	Eisai Co., Ltd. and Biogen Inc. Announces New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025	CI
03/12	Biogen Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-02-2025 12:55 PM
02/12	Tyra Biosciences, Inc. Appoints Heather Faulds as Chief Regulatory Officer, Effective December 8, 2025	CI
29/11	Sector Update: Health Care Stocks Mixed Premarket Friday	MT
29/11	Sector Update: Health Care	MT
28/11	Biogen, Eisai Seek Japan Approval for Alzheimer's Drug At-Home Injection	MT